Dr Zacharoff provided advice for clinicians dealing with fluid guidelines and constraints regarding opioid prescribing.
If we invest in providing addiction treatment that is evidence-based and fundamentally invested in the dignity of every person who needs that treatment, a lot more people are going to find themselves ready to seek it out.
Dr Twillman extensively emphasized the fact that these CDC guidelines are expert- and not evidence-based.
A high level of comorbidity exists between substance use disorders and chronic pain.
Clinical Pain Advisor Articles
- Opioid Use in Chronic Low Back Pain: A Population Study
- Risks Associated With Co-Administration of Aspirin and Other NSAIDs
- FDA Approves Aimovig for Migraine Prevention
- Stages of Low Back Pain Have Specific Sets of Clinical Indicators
- First Non-Opioid Drug Approved for Managing Opioid Withdrawal Symptoms
- Effect of Prescription Drug Monitoring Programs on Fatal, Nonfatal Drug Overdoses
- Standardized SCS Workflow May Effectively Alleviate Failed Back Surgery Syndrome-Related Pain
- Marijuana Legalization and Opioid Prescribing Rates
- Medical Marijuana Users More Likely to Use Prescription Drugs for Medical, Nonmedical Purposes
- Interbrain Coupling During Handholding Associated With Analgesia, Empathy
- IV Tramadol Significantly Reduces Post-Op Pain in Phase 3 Study
- Telehealth-Delivered Behavioral Therapy, Supportive Care Beneficial for Low Back Pain
- Patient-Controlled Analgesia Pumps Have Low Device-Related Error Rates
- Adding Chiropractic to Usual Care Beneficial for Low Back Pain
- Illness Perceptions Mediate Back Pain, Quality of Life in Early Axial Spondyloarthritis